Advocacy for better metabolic monitoring after antipsychotic initiation: based on data from a French health insurance database

References

• Tiihonen J, Taipale H, Mehtälä J, et al. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry. 2019;76(5):499–507.
   PubMed Web of Science ®Google Scholar
• Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders – a systematic review and meta-analysis. Schizophr Bull. 2013;39(2):306–318.
   PubMed Web of Science ®Google Scholar
• Désaméricq G, Schürhoff F, Macquin-Mavier I, et al. Use of antipsychotics: a study from the French national insurance healthcare system database. Pharmacol Pharm. 2015;6:411–419.
   Google Scholar
• Olfson M, King M, Schoenbaum M. Antipsychotic treatment of adults in the United States. J Clin Psychiatry. 2015;76(10):1346–1353.
   PubMed Web of Science ®Google Scholar
• Godin O, Leboyer M, Gaman A, et al. Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: results from the FACE-SZ cohort. Schizophr Res. 2015;168(1–2):388–394.
   PubMed Web of Science ®Google Scholar
• Godin O, Etain B, Henry C, et al. Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort. J Clin Psychiatry. 2014;75(10):1078–1085; quiz 1085.
   PubMed Web of Science ®Google Scholar
• Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645.
   PubMed Web of Science ®Google Scholar
• Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004;89(6):2595–2600.
   PubMed Web of Science ®Google Scholar
• Penninx BWJH, Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci. 2018;20(1):63–73.
   PubMed Web of Science ®Google Scholar
• Hjorthøj C, Stürup AE, McGrath JJ, et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295–301.
   PubMed Web of Science ®Google Scholar
• Rødevand L, Steen NE, Elvsåshagen T, et al. Cardiovascular risk remains high in schizophrenia with modest improvements in bipolar disorder during past decade. Acta Psychiatr Scand. 2019;139(4):348–360.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601.
   PubMed Web of Science ®Google Scholar
• ANSM. Suivi cardio-métabolique des patients traités par antipsychotiques. cited Mar 2010.
   Google Scholar
• De Hert M, Vancampfort D, Correll CU, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry J Ment Sci. 2011;199(2):99–105.
   PubMed Web of Science ®Google Scholar
• Haupt DW, Rosenblatt LC, Kim E, et al. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry. 2009;166(3):345–353.
   PubMed Web of Science ®Google Scholar
• Morrato EH, Newcomer JW, Allen RR, et al. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of medicaid claims data. J Clin Psychiatry. 2008;69(2):316–322.
   PubMed Web of Science ®Google Scholar
• Mitchell AJ, Delaffon V, Vancampfort D, et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med. 2012;42(1):125–147.
   PubMed Web of Science ®Google Scholar
• Moeller KE, Rigler SK, Mayorga A, et al. Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance. Schizophr Res. 2011;126(1–3):117–123.
   PubMed Web of Science ®Google Scholar
• Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954–962.
   PubMed Web of Science ®Google Scholar
• Morrato EH, Druss B, Hartung DM, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry. 2010;67(1):17–24.
   PubMed Web of Science ®Google Scholar
• Morrato EH, Campagna EJ, Brewer SE, et al. Metabolic testing for adults in a state medicaid program receiving antipsychotics: remaining barriers to achieving population health prevention goals. JAMA Psychiatry. 2016;73(7):721–730.
   PubMed Web of Science ®Google Scholar
• Gareri P, De Fazio P, Manfredi VGL, et al. Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. J Clin Psychopharmacol. 2014;34(1):109–123.
   PubMed Web of Science ®Google Scholar
• Harrison SL, Sluggett JK, Lang C, et al. Initiation of antipsychotics after moving to residential aged care facilities and mortality: a national cohort study. Aging Clin Exp Res. 2020 [ cited March 11]. DOI:10.1007/s40520-020-01518-y
   Web of Science ®Google Scholar
• Brodaty H, Aerts L, Harrison F, et al. Antipsychotic deprescription for older adults in long-term care: the HALT study. J Am Med Dir Assoc. 2018;19(7):592–600.e7.
   PubMed Web of Science ®Google Scholar
• Kloosterboer SM, Schuiling-Veninga CCM, Bos JHJ, et al. Antipsychotics in Dutch youth: prevalence, dosages, and duration of use from 2005 to 2015. J Child Adolesc Psychopharmacol. 2018;28(3):173–179.
   PubMed Web of Science ®Google Scholar
• Park SY, Cervesi C, Galling B, et al. Antipsychotic use trends in youth with autism spectrum disorder and/or intellectual disability: a meta-analysis. J Am Acad Child Adolesc Psychiatry. 2016;55(6):456–468.e4.
   PubMed Web of Science ®Google Scholar
• Carton L, Cottencin O, Lapeyre-Mestre M, et al. Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. Curr Pharm Des. 2015;21(23):3280–3297.
   PubMed Web of Science ®Google Scholar
• Menard M-L, Thümmler S, Giannitelli M, et al. Incidence of adverse events in antipsychotic-naïve children and adolescents treated with antipsychotic drugs: results of a multicenter naturalistic study (ETAPE). Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2019;29(12):1397–1407.
   PubMed Web of Science ®Google Scholar
• Chen W, Cepoiu-Martin M, Stang A, et al. Antipsychotic prescribing and safety monitoring practices in children and youth: a population-based study in Alberta, Canada. Clin Drug Investig. 2018;38(5):449–455.
   PubMed Web of Science ®Google Scholar
• Lin EC-L, Shao W-C, Yang H-J, et al. Is abnormal non-high-density lipoprotein cholesterol a gender-specific predictor for metabolic syndrome in patients with schizophrenia taking second-generation antipsychotics? Metab Brain Dis. 2015;30(1):107–113.
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68(Suppl 1):20–27.
   PubMed Web of Science ®Google Scholar
• Musil R, Obermeier M, Russ P, et al. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf. 2015;14(1):73–96.
   PubMed Web of Science ®Google Scholar
• Bonnot O, Dufresne M, Herrera P, et al. Influence of socioeconomic status on antipsychotic prescriptions among youth in France. BMC Psychiatry. 2017;17(1):82.
   PubMedGoogle Scholar
• Melamed OC, Wong EN, LaChance LR, et al. Interventions to improve metabolic risk screening among adult patients taking antipsychotic medication: a systematic review. Psychiatr Serv. 2019;70(12):1138–1156.
   PubMed Web of Science ®Google Scholar
• Ronsley R, Rayter M, Smith D, et al. Metabolic monitoring training program implementation in the community setting was associated with improved monitoring in second-generation antipsychotic-treated children. Can J Psychiatry Rev Can Psychiatr. 2012;57(5):292–299.
   PubMed Web of Science ®Google Scholar
• Ingelsson E, Larson MG, Yin X, et al. Circulating ghrelin, leptin, and soluble leptin receptor concentrations and cardiometabolic risk factors in a community-based sample. J Clin Endocrinol Metab. 2008;93(8):3149–3157.
   PubMed Web of Science ®Google Scholar
• Rosso G, Cattaneo A, Zanardini R, et al. Glucose metabolism alterations in patients with bipolar disorder. J Affect Disord. 2015;184:293–298.
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet Lond Engl. 2009;373(9657):31–41.
   PubMed Web of Science ®Google Scholar
• Tse L, Procyshyn RM, Fredrikson DH, et al. Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension. Int Clin Psychopharmacol. 2014;29(3):125–137.
   PubMed Web of Science ®Google Scholar
• Ehret M, Goethe J, Lanosa M, et al. The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. J Clin Psychiatry. 2010;71(10):1286–1292.
   PubMed Web of Science ®Google Scholar